et al.. Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma.
Glioblastoma multiforme (GBM) is the most common and deadliest of malignant primary brain tumors in adults and is one of a group of tumors referred to as gliomas. Classified as a grade IV (most serious) astrocytoma, its prog nosis is bleak -the median survival time with out treatment is 3 months [1] . The number of new diagnoses made annually is two to three per 100,000 people in the USA and Europe. GBM accounts for 12-15% of all intracranial tumors and 50-60% of astrocytic tumors [2] . The standard treatment is surgery, followed by radiation therapy or combined radiation therapy and chemotherapy, but surgical removal of such tumors only prolongs the typical patient's survival by less than a year. Some drugs have been used for treatment of adult patients with newly diagnosed GBM. The carmustine implant with polifeprosan 20 [3] , temozolomide [4] and bevacizumab [5] have been approved by the US FDA to date. There are several trials that involve many types of therapy, including immunotherapy, anti angiogenic therapy, gene and viral therapy, cancer stem cell therapy, and targeted therapy (personalized medicine) [6, 7, 101] . Therefore, the quest for new drugs and new delivery systems for targeted therapy is still ongoing and could give new hope to fight GBM.
Nanomedicine is the application of nano technology to medicine, and the exploitation of nanoplatforms for cancer treatment holds great promise [8] due to the possibility of tai loring the synthesis of nanoparticles (NPs) in order to produce particles with narrow size distributions and cavities where drugs can be incorporated [9, 10] . To date, there is a lot of evidence that these nanocarrier materials are capable of improving the efficiency of thera peutics through wellestablished targeted
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For reprint orders, please contact: reprints@futuremedicine.com future science group Research Article Locatelli, Naddaka, Uboldi et al. drug delivery (TDD) techniques [11] . TDD is based on the idea that tumor cells overexpress many receptors and biomarkers that can be used as targets for selec tive delivery. Therefore, the development of therapeu tic carriers that can deliver high drug payloads, while protecting the encapsulated drug from degradation and reducing offtarget toxicities, is currently of significant interest [12] . The first generation of drugloaded NPs with applications in medicine date back to the 1970s, when nanoscaled liposomes were developed to deliver their cargo to diseased cells in a 'Trojan horse' fashion [13] . Since then, a new generation of TDD vehicles (e.g., polymeric NPs [PNPs]) has emerged [14] .
PNPs are optimal nanocarriers for TDD due to their small size and ability to entrap efficaciously drug mole cules. These tunable characteristics can help to solve the common problems associated with traditional medicine, such as poor drugs solubility in water and short in vivo lifetime. The main feature of these nanosystems is that their surfaces can be functionalized, exploiting termi nal reactive groups, with specific proteins, peptides or monoclonal antibodies that are able to selectively bind a site of action or a particular target tissue without interacting with other cells and, thus, minimizing side effects and enhancing drug efficiency. The poly(lactic coglycolic acid) (PLGA)blockPEGcarboxylic acid (PLGAbPEG) copolymer is an easytosynthesize material that is emerging as one of the most promis ing system for drug loading and in vivo drug delivery applications. PLGAbPEG is an amphiphilic polymer that selfassembles to generate a targetable system (due to the presence of terminal COOH functional groups) in which the hydrophobic PLGA forms the inner core, while the hydrophilic PEG arranges outside creating a stabilizing shell [15] [16] [17] .
We have recently reported in vitro applications of lipophilic silver (Ag)loaded PNPs derived from the PLGAbPEGCOOH block copolymer against glio blastoma cell lines [18] . We used the chlorotoxin (Cltx) as the targeting agent to show their in vitro targeting ability in the U87MG glioblastoma cell line. Cltx is a 36amino acidlong peptide that specifically binds to MMP2, a protease involved in remodeling the cell microenvironment, particularly the basement mem brane [18, 19] . Indeed, most research today is focused on achieving active targeting and therapeutic advantage of NPs by chemical modifications. To the best of our knowledge, no studies on the TDD of a combination of drugs and metallic NPs to treat in vivo malignant glioma have been reported.
In this study, we report the synthesis of PNPs con taining the drug alisertib (Ali), a selective aurora A kinase (AAK) inhibitor and AgNPs, developed as a TDD system against GBM. An in vitro study on glioma cell lines and in vivo biodistribution and preliminary efficiency evaluations regarding tumor reduction are also described. To the best to our knowledge, this is the first study in which PNPs are radiolabelled with 99m Tc and imaged in vivo.
Materials & methods

Synthesis of Ag@PNPs
The Ag@PNP nanosystem has been character ized previously [17] . Dynamic light scattering (DLS) showed a hydrodynamic diameter of 112.6 ± 2.9 nm with a narrow size distribution (polydispersity index [PDI] = 0.190 ± 0.011) and a zpotential of 35.3 mV. The concentration of Ag was measured by means of atomic absorption spectroscopy (AAS) and it was found to be 22799 ppm, corresponding to a 211.3mM solution.
Synthesis of Ag@PNPs-Cltx
For the Ag@PNPs-Cltx, DLS ana lysis showed a hydro dynamic diameter of 117.4 ± 14.4 nm with a narrow size distribution (PDI = 0.22) similar to the results obtained before Cltx conjugation. The zpotential was 16.2 mV and the concentration of Ag was measured by AAS and was found to be 1402 ppm, corresponding to a 13.0mM solution.
Synthesis of Ag/Ali@PNPs
To synthesise Ag/Ali@PNPs, 50 mg of PLGAbPEG COOH (7 kDa PLGA/3 kDa PEG, 0.005 mmol) and 9 mg of Ali (0.017 mmol) were dissolved into a 1ml dispersion of AgNPs in dimethylsulfoxide (DMSO). The organic phase was mixed with 50 ml of ultra pure water under vigorous stirring, maintaining a water:organic ratio of 10:1 with constant removal of the resulting solution. The mixture was kept under mag netic stirring for 30 min and then purified and concen trated using centrifugal filter devices (Amicon Ultra, Ultracel ® membrane with 100,000 NMWL; Millipore, MA, USA) until the final volume of 5 ml. This disper sion was then filtered on a syringe filter Sterivex™GP polyether sulfone membrane with a 0.22µm pore size (Millipore) and stored at 4°C. DLS ana lysis showed a hydrodynamic diameter of 190.6 ± 0.8 nm and a PDI of 0.09 ± 0.03 with a xpotential of 47.8 ± 13.4 mV. Ag and Ali concentrations were determined using AAS and highperformance liquid chromatography (HPLC) ana lysis, respectively, and they were found to be 2280 ppm of Ag, corresponding to 21 and 404 µM of Ali.
Synthesis of Ag/Ali@PNPs-Cltx
Nhydroxysulfosuccinimide (1.3 mg, 11.0 µmol) and a solution of 1ethyl3(3dimethylaminopropyl) future science group Targeted delivery of silver nanoparticles & alisertib in glioblastoma Research Article carbodiimide 0.28 M (7.1 ml) were added to a suspension of Ag/Ali@PNPs (5 ml) in phosphatebuffered saline (20 ml, 0.01 M) under magnetic stirring. The mixture was left to react at room temperature for 30 min and then Cltx (0.150 µg, 0.038 µmol) dissolved in 1 ml of water was added and the reaction mixture was allowed to react for an additional 8 h. The mixture was then washed with phosphatebuffered saline solution three times and concentrated into centrifugal filter devices (Ami con Ultra, Ultracel membrane with 100.000 NMWL), to a final volume of 5 ml. Finally, Ag/Ali@PNPs-Cltx were filtered on a syringe filter Sterivex™GP polyether sulfone membrane with a 0.22µm pore size and stored at 4°C. DLS ana lysis showed a hydrodynamic diameter of 199.1 ± 0.6 nm with a PDI of 0.21 ± 0.02 and a zpotential of 15.4 ± 4.5 mV. The Ali concentration was determined using HPLC and was found to be 41.8 µM. An elemental ana lysis by atomic AAS gave an average Ag concentration of 2.17 mM.
Trypan blue assay
Cytotoxicity of Ali alone or PNPs either loaded with Ali (Ali@PNPs-Cltx) or with Ali and AgNPs (Ag/Ali@PNPs) were evaluated on U87MG using a trypan blue exclusion dye test. Cells were incubated for 48 and 72 h at concentrations of Ali ranging from 0.001 to 10 µM (Supplementary Material, see online at www. futuremedicine.com/doi/suppl/10.2217/nnm.14.1). Data were analyzed as the percentage of viable cells against the control. Results obtained by the trypan blue assay were analyzed and expressed as the percent age of viable cells against the control (mean ± standard error of the mean). Statistical ana lysis was performed applying the oneway ANOVA test and Dunnett's mul tiple comparison test. For each experimental point, six replicates and three independent experiments were per formed. Linear regression ana lysis was performed by using STATGRAPHICS ® Centurion XVI.
Radiolabeling of the 99m Tc-NPs
Radiolabeling of PNPs was performed using the direct method according to a slightly modified previously described protocol [20, 21] . Briefly, 40 µl of an acidic, aqueous solution containing SnCl 2 (10 mg dissolved in 500 µl of HCl 37%, diluted to 10 ml, 1 mg/ml) was added to 100 µl of pertechnetate eluate. The pH was adjusted to the range of 7, with an aqueous solution of NaHCO 3 0.5 M. Finally, aliquots containing 2 µg of NPs were added and the mixture was shaken hori zontally at room temperature for 30 min. Radioana lysis was performed using acetone and a mixture of pyridine:acetic acid:water (3:5:1.5) as mobile phases and instant thin layer chromatography medium-silica gel (ITLCSG) sheets as the stationary phase.
Stability tests
Stability of the radiolabeled PNPs was assessed towards transchelation, using diethylenetriaminepentaacetic acid (DTPA) and histidine, two widely used chelators for 99m Tc, and in plasma to assess their behavior in a biological medium. Thus, 50 µl of each of the radio labeled preparations was challenged against 450 µl of histidine and DTPA solutions (0.01 M) as well as against plasma. Each sample mixture was incubated in a water bath at 37°C for 1, 3 and 6 h, and was analyzed by ITLCSG using acetone and saline as mobile phases for the DTPA/histidine challenge study, and acetone and a mixture of pyridine:acetic acid:water (3:5:1.5) as mobile phases for the plasma stability study.
Imaging studies in animal models
Radiolabeled PNPs (100 µl, 100-300 µCi) were evalu ated scintigraphically after bolus intra venous injec tion via the tail vein in healthy Swiss mice and severe combined immunodeficiency mice bearing U87MG tumors. All animal experiments were performed in compliance with the European legislation for animal welfare. Animals were anesthetized immediately after injection by the intraperitoneal injection of a proper anesthetizing solution -0.5 ml of ketamine hydrochlo ride (100 mg/ml), 0.25 ml of xylazine (20 mg/ml) and 4.25 ml of NaCl 0.9% (dose: 0.1 ml/10 g of animal weight administered intraperitoneally). The animals were placed on the camera approximately 5 min after tracer injection and dynamic images of the anesthetized mice were obtained between 10 and at least 60 min postinjection using a highresolution gcamera system, which has been described elsewhere [22, 23] .
Tumor decrease studies
In the control group, no treatment was applied. In the Ag@PNPs-Cltx group, 100 µl of a 5.97mM AgNPs solution was injected. In the Ali@PNPs-Cltx group, 100 µl of a 0.11mM Ali solution was injected and, in the Ag/Ali@PNPs-Cltx group, 100 µl of a solution contain ing 0.11mM Ali (5.93 mM in Ag) was injected. All sam ples were injected at day 24 and were not radiolabeled in order to avoid further dilution and maximize the quantity of NPs and drug injected. The tumor size was calculated every day according to the formula 0.5 × length × width 2 and mouse weight was also measured until day 55. Since five animals were initially used in each group, the mean value and the standard deviation were calculated for each group. Both values were extracted until the number of surviving animals decreased to three. The experiment ended at day 55 because animals in the control group, as well as other groups, started to die, and the tumor size was in some cases too large, meaning that animals had to be sacrificed.
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Results
Chemistry & nanotechnologies
Polyvinylpyrrolidone (PVP)capped AgNPs were synthe sized as reported in the experimental section. AgNPs were coated on their surface with ethyl 11mercaptoundecano ate 1, obtained as previously reported [24, 25] in order to make them lipophilic and stable in organic solvents and, thus, allowing their entrapment into the PNPs. Ligand 1 was designed with: a terminal thiol group that strongly binds to Ag; a connecting aliphatic chain that ensures sta bility in the system; and a terminal ester group in order to increase solubility in common organic solvents. After incu bation of PVPcapped AgNPs with ligand 1, lipophilic AgNPs1 were washed by centrifugation and redispersed in DMSO. The efficacy of this coating was previously proved with 1 HNMR and DLS analyses [18] .
Next, AgNPs1 were entrapped into PNPs using the nanoprecipitation technique [26] . The amphiphilic PLGAbPEGCOOH copolymer was selected to create biocompatible, biodegradable and watersoluble micelles able to circulate for long periods of time in the blood stream. Therefore, the organic solution of AgNPs1 and the copolymer was added dropwise to a larger amount of ultrapure water under vigorous stirring. The resulting Ag@PNPs were characterized as reported previously [18] . It is worth noting that, in this system, the AgNPs are preserved from dissolution by doublelayer protection. The organic thiol, due to its high affinity for the parti cle surface and low exchange rate, stabilizes the surface, while the PLGAbPEG nanocarrier erects a defensive shell against potentially oxidizing agents ( Figure 1 ) [27] .
Exploiting the nanoprecipitation technique, Ali was entrapped into the same polymeric system. The DLS ana lysis of the obtained Ali@PNPs showed a hydrodynamic radius of 80.5 ± 0.9 nm with a PDI of 0.120 ± 0.004 and a zpotential of 51.6 mV. Finally, the simultaneous entrap ment into the same nanocarriers of both AgNPs1 and Ali was investigated; we first dissolved Ali in dimethylsulfox ide containing AgNPs1 and copolymer, and then we used the nano precipitation techniques to create micelles. After purification, the Ag/Ali@PNPs were fully characterized; DLS ana lysis of this system showed a hydrodynamic diameter of 190.6 ± 0.8 nm with a narrow size distribu tion (PDI = 0.09 ± 0.03) and a zpotential of 47.8 mV. Once fabricated, all three nanosystems were conju gated with Cltx. Docking was achieved through amide bond formation between the carboxylic acids at the par ticle's surface and the free amine group of the peptide using the classical 1ethyl3(3dimethylaminopropyl) carbo diimide chemistry. The Ag@PNPs-Cltx, Ali@ PNPs-Cltx and Ag/Ali@PNPs-Cltx obtained were fully characterized using DLS, transmission electron microscopy and AAS (Figure 2) .
Ag@PNPs-Cltx have already been reported and char acterized by us [18] . DLS ana lysis of Ali@PNPs-Cltx con firms that the particle's dimensions are maintained with a hydrodynamic radius of 98.2 ± 3.8 nm and a narrow size distribution (PDI = 0.160 ± 0.009). The zpotential was found to be 23.2 mV, and the Ali concentration was determined using HPLC ana lysis and was found to be 120.8 µM. Regarding Ag/Ali@PNPs-Cltx, DLS ana lysis revealed a hydrodynamic diameter of 199.1 ± 0.6 nm and a PDI of 0.210 ± 0.018. The zpotential (15.4 mV) became less negative after Cltx conjugation. The Ali concentration was determined using HPLC ana lysis and was found to be 41.8 µM, while the Ag concentration was measured using AAS ana lysis and was found to be 234 ppm, corresponding to a 2.17mM solution.
In vitro biological studies
The effect of Ag@PNPs-Cltx on the U87MG human glioblastoma cell line and Balb/3T3 immortalized fibroblasts has already been reported, and cellspecific recognition of U87MG compared with Balb/3T3 cell lines, via Cltx, was observed. The uptake of Ag was also quantified and a cytotoxic effect corresponding to an IC 50 of 45 µM was found after 72 h of exposure [18] . In the present study, a comparison of these results with Ali alone and Ali@PNPs-Cltx, and the evaluation of the synergistic effect between AgNPs and Ali both loaded in micelles (Ag/Ali@PNPs-Cltx) was carried out.
The range of concentrations tested, related to the amount of Ali for all the compounds, was 0.001-10 µM, corresponding to concentrations of 0.00005-0.5 µM of Ag in Ag/Ali@PNPs-Cltx. Increasing concentrations and exposure times induced a statistically significant decrease in cell viability compared with the untreated cells (control: 100% cell viability) for all the compounds tested (Figure 3 ). DMSO was used to dissolve Ali and it was tested, as a solvent control, at a concentration of 0.2% v/v. DMSO did not show any statistically signifi cant toxicity when administered as the negative control. In fact, the cell viability after 48 and 72 h of exposure was 98 and 99%, respectively. At each examined time point, Ali@PNPs-Cltx were more toxic than Ali alone; comparing the IC 50 of Ali@PNPs-Cltx (0.02 µM) and Ag/Ali@PNPs-Cltx (0.01 µM of Ali and 0.0005 µM of Ag), the latter was more toxic, but only after 72 h of incubation ( Figure 3B ). Furthermore, Ali@PNPs-Cltx showed a nonlinear dose-effect relationship after both 48 and 72 h of exposure with almost complete cell death at 5 and 10 µM; by contrast, the toxicity of Ag/Ali@PNPs-Cltx remained stable at approximately 45 and 30% cell viability at doses from 0.1 to 10 µM, after 48 and 72 h of exposure, respectively (Figure 3 ).
Radiolabeling
In vivo biodistribution was assessed using NPs radio labeled with 99m Tc and highresolution scintigraphic imaging. All of the products of this study were directly radiolabeled [21] with high efficiency >95%, and radio labeled products demonstrated good stability properties. Transchelation against DTPA and histidine was evalu ated by ascending ITLCSG ( Tc (41.5 ± 5.5%). The three NPs remained almost intact (>94%) after 1 h postincubation, with no signifi cant 99m Tc dissociation in favor of donor groups that are always present in plasma proteins. Nevertheless, further incubation resulted in the formation of larger radiocom plexes, as shown by the pyridine:acetic acid:water mixture quality control. At 6 h post incubation, only a fraction of radiolabeled NPs remained intact (31 ± 2.1% for Ag/Ali@ PNPs-Cltx 99m Tc, 17 ± 1.9% for Ali@PNPs-Cltx 99m Tc and 24 ± 3.2% for Ag@PNPs-Cltx 99m Tc).
In vivo biodistribution & therapeutic effect
In vivo studies in tumorbearing mice have shown noticeable concentrations of the NPs in their tumors. Out of all tested products, the highest concentration was observed for the full system Ag/Ali@PNP-Cltx 99m Tc. In Figure 4 & Supplementary Figure 11 , succes sive 2min frames of a tumorbearing mouse injected with Ag@PNPs 99m Tc and Ag/Ali@PNP-Cltx 99m Tc are shown. A significantly higher concentration of Ag/ Ali@PNP-Cltx 99m Tc on the left shoulder, where the tumor is, compared with Ag@PNPs 99m Tc (without the targeting agent Cltx) can be observed.
Quantitative ana lysis ( Supplementary Figures 11 & 12 ) of the 2min frames shows a concentration of 0.6% for Ag@PNPs 99m Tc and 5% for Ag/Ali@PNP-Cltx 99m Tc in the tumor. This concentration is considered signifi cantly different between the two formulations, as well as between Ag/Ali@PNP-Cltx 99m Tc and normal tissue (<2%). In addition, the concentration in the liver drops from 80% for Ag@PNPs 99m Tc to 60% for Ag/Ali@ PNP-Cltx 99m Tc, and a noticeable and steady increase in the concentration in the bladder (from 3 to 7%) for Ag/ Ali@PNP-Cltx 99m Tc compared with Ag@PNPs 99m Tc is observed.
For the initial assessment of a decrease in tumor size, 20 mice were divided into four groups, each one consist ing of five animals -control, Ag@PNPs-Cltx, Ali@ PNPs-Cltx and Ag/Ali@PNPs-Cltx. The compara tive measurements of the average tumor size and mouse weight for the four groups are given in Figure 5 . These results are comparable and match those obtained in the in vitro test (Table 1) .
Discussion
In this work we propose a new method for the synthesis of PNPs loaded with Ali and AgNPs to be used as an anticancer therapy.
All of the nanosystems reported have been obtained with an average diameter of less than 200 nm, which is wildly recognized as a good range for drug delivery appli cations and medical purposes [28] . Ag/Ali@PNPs have a larger diameter that is probably caused by the simultane ous incorporation of two different agents into the PNPs, which remains a challenging task. The nanosystems have highly negative zpotentials due to the presence of a large number of carboxylic acid groups on the micelle's outer shell. Negatively charged NPs have shown prolonged blood circulation and are generally less toxic compared with positively charged NPs [29, 30] . After the conjugation reactions, the zpotential was less negative, probably due to the loss of free carboxylic acids groups, which are now involved in the peptide conjugation.
Ali has been chosen as pharmacologic model for drug loading because of its effect as a selective AAK inhibitor and because its application against solid tumors (epi thelial ovarian, fallopian tube and primary peritoneal carcinoma) is well known [31] [32] [33] . In this work, we also studied the synergic effect of Ali and AgNPs. AgNPs have already been proposed as anticancer agents because of their intrinsic toxic properties [34, 35] , and the AgNPs' cytotoxic effect against cancer cells has already been observed in vitro on U87MG cells, human leukemic K562 cells [36] and in vivo [37] .
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Tumor Tumor Regarding the stability of the radiolabeled NPs, DTPA and histidine challenges are the most efficient methods to determine stability. DTPA and histidine are considered two of the most efficient chelators for 99m Tc, because they have the ability to complex with the radiometal in various oxidation states [38, 39] . The moder ate stability that all radiolabeled NPs present in DTPA after 1 h of incubation is expected considering the strong affinity that 99m Tc has for DTPA. Nevertheless, such conditions are never present in vivo, and, therefore, histi dine challenge, which showed very good stability proper ties even after 6 h of incubation, provides more reliable evidence that these 99m TcNPs will have good in vivo properties, since histidine is a molecule widely present in living organisms as a protein building material. Addi tionally, plasma stability studies are generally used as a means to indicate in vivo stability, since interaction with plasma proteins may alter the initial structure and/or characteristics of the radiolabeled NP, something that can ultimately result in the loss of its designed biological function. Plasma studies showed good stability proper ties of the radiolabeled NPs. The formation of larger radiocomplexes in plasma after 6 h may be attributed to the plethora of biomolecules existing in a biological environment that contain atoms and/or groups able to chelate and stabilize the 99m Tc core, or even compete for Targeted delivery of silver nanoparticles & alisertib in glioblastoma Research Article the limited NP surface, altering the NP's initial structure [40] and causing 'flocculation' of the NP. The results of this study have revealed that, even after 6 h of incubation, the radiometal stays complexed on the NPs as no reoxidation to pertechnetate took place in the in vitro conditions that were chosen specifically to resemble those of the human body.
All imaging studies in vivo indicated, as expected, that NPs were present in the liver, as well as a slow -but continuous -increase in the concentration in bladder. The concentration in the tumor of the nontargeted Ag@PNPs 99m Tc was approximately 0.6% at 60 min postinjection, and this is almost certainly due to the enhanced permeability and retention effect. Taking into account that this value is almost double the con centration in normal tissue (~0.3%) we can say that this is quite encouraging for future studies.
For Ag/Ali@PNP-Cltx 99m Tc, the concentration in liver decreased from 80 to 60% and, therefore, the effect of the targeting peptide is quite clear. This result, combined with the increased concentration in the blad der (from 3 to 7%), provides strong evidence that Ag/ Ali@PNP-Cltx 99m Tc has favorable kinetic in vivo properties when compared with Ag@PNPs 99m Tc, thus providing better scintigraphic images and as well as probably being more effective as a therapeutic agent. The potential of Ag/Ali@PNP-Cltx as a therapeutic delivery vehicle to cancer cells is also suggested by the significantly higher uptake of Ag/Ali@PNP-Cltx 99m Tc compared with other 99m TcPNPs in tumor tissue and the comparatively higher concentration of the nanofor mulation in the tumor compared with normal tissue ( Supplementary Figures 11 & 12) .
The results for tumor size show that treating the mice with Ag@PNPs-Cltx did not have a significant effect on tumor size. On the other hand, Ali@PNPs-Cltx resulted in a slowdown in tumor growth compared with the con trol and Ag@PNPs-Cltx groups. It should be noted that it was only possible to measure tumor size from day 36 and on the day of Ali@PNPs-Cltx injection. When Ag/Ali@PNPs-Cltx was injected, the development of the tumor was altered compared with the three other groups, and a decrease in tumor size was noticeable from day 48. The weight of the mice was constant for all groups, except for the Ag/Ali@PNPs-Cltx group, where weight loss was observed after day 48, which correlates with the observed tumor decrease.
Data in Table 1 support the argument that a syner gistic effect with Ag/Ali@PNPs-Cltx takes place. The in vitro results at 72 h and the in vivo effect after day 48 showed that the decrease in tumor size was greater than with the other nanosystems [41] .
It is still uncertain and currently under debate whether the toxicity of AgNPs is a particlespecific effect [42] or whether it is caused by the dissolution of Ag + ions [43, 44] . In our system, the synergistic effect may be based on the coexistence of the drug with Ag + ions formed from slow AgNPs dissolution, once they are released from the protective polymeric shell.
Since the synergic effect of drugs and NPs could have some advantages in the drug delivery and thera peutics field, it will be important in the near future to better investigate this both in vitro and in vivo, maybe also increasing the AgNP concentration and analyzing different effects induced by these nanomaterials, as well as assessing alternative administration protocols.
Conclusion
In conclusion, we have reported the synthesis of some novel theranostic agents containing the smallmolecule Ali and AgNPs. 99m Tcradiolabeling of the nanocarrier allowed us to see the in vivo biodistribution in U87MG tumor bearing mice, the IC 50 at 72 h and the tumor reduction in vivo that was obtained with Ag/Ali@ PNPs-Cltx, which couples the two agents together and promotes a synergistic effect. These results convey the potential of this novel theranostic agent for TDD.
Future perspective
The potential of targeted NPs for cancer treatment is immense, and a variety of systems have been devel oped and studied. However, systems bearing multiple therapeutic agents with a synergistic effect on tumor reduction are relatively novel. Thus, more studies are needed to explain the synergistic effect of the two cyto toxic agents. The understanding of this mechanism will allow the development of novel systems bearing multiple components with synergistic effect for the treatment of different types of cancer.
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Executive summary
Background • Glioblastoma multiforme (GBM) is a malignant primary brain tumor with a bleak prognosis. The survival time without treatment is 3 months. • Nanomedicine and targeted drug delivery are a powerful approach for cancer treatment.
Materials & methods
• Synthesis of nanocarriers containing silver nanoparticles with alisertib have been developed. • Resulting polymeric nanoparticles have been conjugated with the peptide chlorotoxin and radiolabeled with 99m Tc. • In vitro toxicity against GBM cell lines showed a synergistic effect between silver and alisertib. • In vivo radiolabeling showed a GBM-targeted biodistribution of the nanoparticles and a therapeutic effect.
Conclusion & future perspective
• A targeted strategy using a polymeric nanoparticles for drug delivery against GBM has been developed. • This approach may be applied for future nanomedicine applications.
